Pharmaceutical Formulation Intermediates

Aprepitant Pellets 40.0% – Ready to Fill Into Capsules (Dose: 40 mg, 80 mg, or 125 mg)

• Matches with the innovator product in terms of the dissolution profile
• Conducted and cleared multimedia dissolution studies against the innovator product
• Offers a non-infringing product
• Do offer development services in case of a requirement for different formulation/dosage/strength
• Offer complete technical package for registrations in all regulated/semi regulated markets

Azithromycin Pellets/Powder 7.5%, 20%, 40% – Suitable for Capsules, Tablets, Suspension

• The objective of developing Azithromycin taste masked micro pellets (Multiple unit particulate system i.e. MUPS) by aqueous technology is to fill the micro pellets in to capsule, are compressed into tablet and also are constituted to make the oral suspension. MUPS has distinct advantages over single unit system such as multiple unit particles get distributed throughout the Gl tract thereby avoiding localized accumulation. Micro pellets developed by aqueous technology have also advantage of avoiding the use of organic solvents.
• We do offer development services in case of a requirement for different formulation/dosage/strength
• Offer complete technical package for registrations in all regulated/semi regulated markets
• Products protected by ongoing Patents are not offered by MKPPL.

Clarithromycin Taste Masked Granules 27.5%, 30%, 33%, 42%, 43.75% – Suitable for Capsules, Tablets, Suspensions (DOSE: 125 mg, 250 mg, 500 mg)

Clarithromycin is used to treat a wide variety of bacterial infections including the one’s caused by H. PYLORI. This medication can also be used in combination with anti-ulcer medications to treat certain types of stomach ulcers. It may also be used to prevent certain bacterial infections.

• Murli Krishna Pharma Pvt. Ltd. is a leading global PFI manufacturer and supplier for Clarithromycin PFI as granules.
• The process of Manufacturing Clarithromycin Taste Masked Pellets of MKPPL is completely aqueous based. No solvent has been used in any stage of manufacturing process. This process effectively masks the taste of the drug without compromising the dissolution rate.
• We offer development services if different formulation/dosage/strength are required.
• Complete technical package for registrations in all regulated/semi regulated markets are available
• Products protected by ongoing Patents are not offered by MKPPL.

Dexlansoprazole DDR Pellets 17%, 20%, 22.5%, 23% – Suitable for Capsules (Dose: 30 mg, 60 mg)

The pharmaceutical form of dexlansoprazole is based on the unique technology of modified dual release. The active ingredient is released in two phases at different pH values and with a time interval. Consequently, the drug achieves two peak concentrations in the blood, and the total serum concentration of dexlansoprazole is three times higher.

• MKPPL has developed Dexlansoprazole pellets by aqueous technology to match the dissolution profile of Dexlansoprazole Pellets with Innovator.
• The product developed is comparable with innovator with respect to dissolution profile of the marketed product.
• We offer development services if different formulations/dosages/strengths are required
• Offer complete technical package for registrations in all regulated/semi regulated markets
• Products protected by ongoing Patents are not offered by MKPPL.

Duloxetine HCL EC Pellets – Suitable for filling 20mg, 40mg & 60mg Capsules.

• Release pattern compared with innovator
• MKPPL objective is to develop duloxetine pellets by aqueous technology. Pellets developed by aqueous technology have advantage of avoiding the use of organic solvents.
• All the ingredients are available for both FBC process and all the equipment’s including analytical instruments like HPLC, FTIR, GC and dissolution apparatus are available to develop duloxetine pellets.
• Offer complete technical package for registrations in all regulated/semi regulated markets.

Esomeprazole EC Pellets / MUPS / Granules 8.5%, 22.5% – Suitable for Capsules, Tablets (dose: 20 mg, 40 mg)

• Esomeprazole is the chiral form of omeprazole. The product is manufactured as enteric coated pellets by aqueous technology to match with Innovator without use of organic solvent.
• The product developed is comparable with innovator with respect to dissolution profile of the marketed product.
• The quality of the pellets is based on the in-vitro dissolution test besides the assay and the impurity profile. The time dissolution values are direct measures of the coating efficiency and hence optimum therapeutic efficacy as it has a co-relation with in-vivo behaviors.
• We do offer development services in case of a requirement for different formulation/dosage/strength
• Offer complete technical package for registrations in all regulated/semi regulated markets
• Products protected by ongoing Patents are not offered by MKPPL.

Esomeprazole is also proton pump inhibitor and is one of the blockbuster molecule that is used in the treatment of ulcer.

Everolimus Granules – Available as Nanoparticles with 2.68% & 5% Strengths.

• MKPPL is the first to come up with pellet based approach for immune suppressants.
• Facilitates direct filling into capsules and can be easily employed in tableting. Nano particles can be effectively used for manufacturing of ointments (Tacrolimus) and solutions (Everolimus).
• MKPPL pellet advantages includes using a micro emulsion technology. No cyclization of the drug, hence less delta lactones formation.
• Coated pellets, hence the formulator does not require a contained facility for finished formulation.
• Offer complete technical package for registrations in all regulated/semi regulated markets.

Lansoprazole EC Pellets Suitable for filling in 15mg & 30mg Capsules, MUPS, Premix (sachet) & 30mg Tablets.

Lansoprazole is a second-generation proton pump inhibitor and is one of the blockbuster molecule that is used in the treatment of ulcers.

• Release pattern compared with innovator -Prevacid delayed-release capsules and Prevacid solutab delayed-release orally disintegrating tablets.
• A comparative dissolution was conducted for Lansoprazole capsules of Murli Krishna Pharma and prevacid capsules which compare favorably.
• The focal intent of the MKPPL was to develop a stable; pharmaceutically equivalent, robust and delayed release micro pellet formulation of Lansoprazole for both capsule and orally disintegrating tablets.
• Offer complete technical package for registrations in all regulated/semi regulated markets.

Mebeverine HCL Extended Release Pellets – Suitable for filling in 135mg & 200mg Capsules.

• MKPPL achieved the desired sustained release profile equivalent to innovator
• Mebeverine is an antispasmodic medicine which is taken to relieve bloating and cramp pain in the lower abdomen. These symptoms are commonly associated with the gastrointestinal condition called irritable bowel syndrome.
• MKPPL aims to deliver Mebeverine as an inhibitor of calcium-depot replenishment. Musculotropic compounds act directly on the gut muscles at the cellular level to relax them. This relieves painful muscle spasms of the gut without affecting its normal motility.
• Offer complete technical package for registrations in all regulated/semi regulated markets.

Orlistat Pellets 50% – Ready to Fill Into Capsules (Dose: 60 mg, 120 mg)

Orlistat is a lipase inhibitor for obesity management that acts by inhibiting the absorption of dietary fats. Orlistat can also help to reduce risk factors, such as high blood pressure, high cholesterol and high blood sugar which, if not treated, could lead to other diseases such as hypertension and diabetes.

• MKPPL has developed Orlistat pellets equivalent to innovator product using aqueous technology.
• Multimedia Dissolution Profile is compared with Marketed Product and similarity results were within limits in all media.
• We do offer development services in case of a requirement for different formulation/dosage/strength
• Offer complete technical package for registrations in all regulated/semi regulated markets
• MKPPL offers a patent non-infringing product.